| |SEPTEMBER 20249Eli Lilly announced that it will invest $1.8 billion in two manufacturing facilities in Ireland to increase production of its highly popular obesity medication and a recently approved treatment for Alzheimer's disease.The funding is a continuation of Lilly's dedication to increasing production, specifically for its popular diabetes and obesity medications, Mounjaro and Zepbound. Since 2020, the company has invested more than $20 billion to enhance its manufacturing sites in the U.S. and Europe.The new facility in Kinsale, Ireland, where Lilly's obesity and diabetes medicines started being produced last year, received an investment of about $800 million from the company. The need for Zepbound has been greater than the available amount for the majority of the year. The remaining funds will be used to grow the drug company's site in Limerick, Ireland, where it will specialize in manufacturing active biological components for specific medications, such as those used to treat Alzheimer's.Lilly's Alzheimer's drug was approved in the U.S. in July and is now being assessed by health regulators in Europe and the UK. Novo Nordisk, a competitor from Denmark, has also invested billions in production to increase the supply of its successful weight-loss drug Wegovy, through a large deal worth $11 billion to acquire three sites from Catalent, a contract manufacturer.Since its launch in December, Zepbound quickly gained a market share of approximately 40 per cent in the United States. Analysts predict that with Lilly expanding its production capacity, the market may be evenly divided between Lilly and Novo Nordisk by the end of the year. POQuantum BioPharma Ltd, a company focused on developing a range of new assets and biotechnology solutions, has revealed that its subsidiary, HUGE Biopharma Australia Pty Ltd, has partnered with Ingenu CRO Pty Ltd to carry out a clinical study on tracking disease progression in primary progressive multiple sclerosis (MS) patients. This research will help in conducting a upcoming phase 2 clinical trial involving Lucid-21-302.."We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research programme and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, vice-president, scientific and clinical affairs at Quantum Biopharma.Quantum BioPharma focuses on creating a range of cutting-edge products and biotech treatments for difficult neurodegenerative, metabolic, and alcohol misuse disorders, with various drug candidates in development.Quantum BioPharma is dedicated to the research and development of Lucid-MS through its subsidiary, Lucid Psycheceuticals Inc. Lucid-MS, a patented novel substance, has been demonstrated to stop and undo myelin deterioration, the primary cause of multiple sclerosis, in preliminary animal studies. POELI LILLY FUNDS $1.8 BLN IN IRELAND SITES TO BOOST OBESITY DRUG PRODUCTIONQUANTUM PARTNERS WITH INGENU CRO FOR STUDY ON MS DISEASE PROGRESSIONTOP STORIES
< Page 8 | Page 10 >